Abstract
siRNA technology presents a helpful means of gene silencing in mammalian cells. Advancement in the field includes enhanced attentiveness in the characterization of target and off-target effects employing suitable controls and gene expression microarrays. These will permit expansion in the measurement of single and multiple target combinations and also permit comprehensive efforts to understand mammalian cell processes. Another fact is that the delivery of siRNA requires the creation of a nanoparticulate vector with controlled structural geometry and surface modalities inside the targeted cells. On the other hand, dendrimers represent the class of carrier system where massive control over size, shape and physicochemical properties makes this delivery vector exceptional and favorable in genetic transfection applications. The siRNA therapeutics may be incorporated inside the geometry of the density controlled dendrimers with the option of engineering the structure to the specific needs of the genetic material and its indication. The existing reports on the siRNA carrying and deliverance potential of dendrimers clearly suggest the significance of this novel class of polymeric architecture and certainly elevate the futuristic use of this highly branched vector as genetic material delivery system.
Keywords: Dendrimer, siRNA, nanocarrier, drug delivery, therapy.
Current Pharmaceutical Design
Title:siRNA Therapy, Challenges and Underlying Perspectives of Dendrimer as Delivery Vector
Volume: 21 Issue: 31
Author(s): Rakesh Kumar Tekade, Rahul G.S. Maheshwari, Piyoosh A. Sharma, Muktika Tekade and Abhay Singh Chauhan
Affiliation:
Keywords: Dendrimer, siRNA, nanocarrier, drug delivery, therapy.
Abstract: siRNA technology presents a helpful means of gene silencing in mammalian cells. Advancement in the field includes enhanced attentiveness in the characterization of target and off-target effects employing suitable controls and gene expression microarrays. These will permit expansion in the measurement of single and multiple target combinations and also permit comprehensive efforts to understand mammalian cell processes. Another fact is that the delivery of siRNA requires the creation of a nanoparticulate vector with controlled structural geometry and surface modalities inside the targeted cells. On the other hand, dendrimers represent the class of carrier system where massive control over size, shape and physicochemical properties makes this delivery vector exceptional and favorable in genetic transfection applications. The siRNA therapeutics may be incorporated inside the geometry of the density controlled dendrimers with the option of engineering the structure to the specific needs of the genetic material and its indication. The existing reports on the siRNA carrying and deliverance potential of dendrimers clearly suggest the significance of this novel class of polymeric architecture and certainly elevate the futuristic use of this highly branched vector as genetic material delivery system.
Export Options
About this article
Cite this article as:
Tekade Kumar Rakesh, Maheshwari G.S. Rahul, Sharma A. Piyoosh, Tekade Muktika and Chauhan Singh Abhay, siRNA Therapy, Challenges and Underlying Perspectives of Dendrimer as Delivery Vector, Current Pharmaceutical Design 2015; 21 (31) . https://dx.doi.org/10.2174/138161282131151013192116
DOI https://dx.doi.org/10.2174/138161282131151013192116 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Managing Erectile Dysfunction in Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Current Status of Carotid Stenting
Current Vascular Pharmacology Platelet Microparticles Induce Angiogenesis and Neurogenesis after Cerebral Ischemia
Current Neurovascular Research Role of the Renin-Angiotensin-Aldosterone System in the Pathogenesis of Atherosclerosis
Current Pharmaceutical Design Evaluation of Gene and Cell-Based Therapies for Cardiac Regeneration
Current Stem Cell Research & Therapy Fibroblast Growth Factor-Inducible 14: Multiple Roles in Tumor Metastasis
Current Molecular Medicine Importance of Aquaporins in the Physiopathology of Brain Edema
Current Pharmaceutical Design Brachial-Ankle Pulse Wave Velocity in the Measurement of Arterial Stiffness: Recent Evidence and Clinical Applications
Current Hypertension Reviews Mechanisms of Melatonin in Alleviating Alzheimer’s Disease
Current Neuropharmacology Blood Coagulation and the Risk of Atherothrombosis
Current Genomics Peptides for Tumour Therapy and Diagnosis: Current Status and Future Directions
Current Medicinal Chemistry Role of the heme oxygenase-adiponectin-atrial natriuretic peptide axis in renal function
Current Pharmaceutical Design MicroRNA-208a Potentiates Angiotensin II-triggered Cardiac Myoblasts Apoptosis via Inhibiting Nemo-like Kinase (NLK)
Current Pharmaceutical Design TNF-α and IL-8 in Acute Stroke and the Modulation of these Cytokines by Antiplatelet Agents
Current Neurovascular Research Ischemic Colitis: Current Diagnosis and Treatment
Current Drug Targets Cardio-vascular Activity of Catestatin: Interlocking the Puzzle Pieces
Current Medicinal Chemistry Dyslipidemia as a Risk Factor for Ischemic Stroke
Current Topics in Medicinal Chemistry Melatonin and Melatonin Agonists as Adjunctive Treatments in Bipolar Disorders
Current Pharmaceutical Design GP IIb / IIIa Blockade in Elective Percutaneous Coronary Intervention
Current Pharmaceutical Design Histological Alterations in the Testicular Tissue Induced by Sildenafil Overdoses
Drug Metabolism Letters